Affinity Asset Advisors
Latest statistics and disclosures from Affinity Asset Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, SPY, BBIO, VINC, MORF, and represent 48.78% of Affinity Asset Advisors's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$63M), SPY (+$43M), Arya Sciences Acquisition -a (+$6.9M), SWTX (+$6.4M), OCUL, BBIO, MRTX, TVTX, SAVA, EDIT.
- Started 23 new stock positions in EDIT, BLI, FOLD, Renovacor, ASLN, Procept Biorobotics Corp, UTHR, CRVS, XENE, SPY. MRTX, TRIL, Tango Therapeutics, ENVI, BHVN, IPHA, Renovacor, SEER, Arya Sciences Acquisition -a, TVTX, KROS, SAVA, RFL.
- Reduced shares in these 10 stocks: ARKG (-$21M), CVAC (-$11M), PTGX (-$6.3M), ZNTL, , XLRN, IONS, MRNA, MGNX, EPIX.
- Sold out of its positions in ARKG, ALNY, APLS, AXSM, Bctg Acquisition Corp, CVRX, CEREW, Chardan Healthcr Acqstn 2, CGEM, EPIX. IONS, ITOS, KALV, MGNX, MRSN, MRNA, PTGX, QSI, CVAC.
- Affinity Asset Advisors was a net buyer of stock by $128M.
- Affinity Asset Advisors has $396M in assets under management (AUM), dropping by 41.76%.
- Central Index Key (CIK): 0001773195
Tip: Access up to 7 years of quarterly data
Positions held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Affinity Asset Advisors
Companies in the Affinity Asset Advisors portfolio as of the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 22.2 | $88M | +250% | 700k | 125.71 | |
| Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) | 10.8 | $43M | NEW | 100k | 429.14 | |
| Bridgebio Pharma (BBIO) | 7.7 | $31M | +18% | 654k | 46.87 | |
| Vincerx Pharma Com New (VINC) | 4.1 | $16M | +19% | 1.0M | 16.17 | |
| Morphic Hldg (MORF) | 3.9 | $15M | +9% | 271k | 56.64 | |
| Inari Medical Ord (NARI) | 2.8 | $11M | +58% | 135k | 81.10 | |
| Kura Oncology (KURA) | 2.5 | $9.9M | +24% | 530k | 18.73 | |
| Springworks Therapeutics (SWTX) | 2.0 | $8.0M | +404% | 126k | 63.44 | |
| Cerevel Therapeutics Hldng I (CERE) | 1.9 | $7.7M | +29% | 260k | 29.50 | |
| Ocular Therapeutix (OCUL) | 1.9 | $7.5M | +200% | 750k | 10.00 | |
| Travere Therapeutics Note 2.500% 9/1 (Principal) | 1.8 | $7.1M | 7.0M | 1.01 | ||
| Arya Sciences Acquisitn Corp Class A Ord Shs | 1.8 | $6.9M | NEW | 703k | 9.88 | |
| Aclaris Therapeutics (ACRS) | 1.6 | $6.3M | +27% | 350k | 18.00 | |
| Acceleron Pharma (XLRN) | 1.5 | $6.1M | -35% | 35k | 172.11 | |
Setup an alertAffinity Asset Advisors will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Arya Sciences Acqu Corp Iv Cl A (ARYD) | 1.5 | $6.0M | -14% | 600k | 10.06 | |
| Nautilus Biotechnology (NAUT) | 1.5 | $6.0M | +8% | 975k | 6.14 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.4 | $5.7M | +79% | 36k | 159.40 | |
| Zentalis Pharmaceuticals (ZNTL) | 1.3 | $5.2M | -45% | 78k | 66.65 | |
| Mirati Therapeutics (MRTX) | 1.2 | $4.9M | NEW | 28k | 176.91 | |
| Travere Therapeutics (TVTX) | 1.2 | $4.9M | NEW | 200k | 24.25 | |
| Cassava Sciences Put Option (SAVA) | 1.2 | $4.7M | NEW | 75k | 62.08 | |
| Curis Com New (CRIS) | 1.1 | $4.5M | -11% | 575k | 7.83 | |
| Cytokinetics Com New (CYTK) | 1.1 | $4.5M | +78% | 125k | 35.74 | |
| Establishment Labs Holdings Ord (ESTA) | 1.1 | $4.3M | +200% | 60k | 71.58 | |
| Editas Medicine Put Option (EDIT) | 1.0 | $4.1M | NEW | 100k | 41.08 | |
| Iovance Biotherapeutics (IOVA) | 0.9 | $3.7M | +50% | 150k | 24.66 | |
| Nanostring Technologies (NSTG) | 0.9 | $3.6M | +400% | 75k | 48.01 | |
| Trillium Therapeutics Com New (TRIL) | 0.9 | $3.5M | NEW | 200k | 17.56 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.9 | $3.4M | +203% | 203k | 16.70 | |
| Bellus Health Com New (BLU) | 0.8 | $3.3M | +77% | 532k | 6.14 | |
| Rafael Hldgs Com Cl B Put Option (RFL) | 0.8 | $3.1M | NEW | 101k | 30.73 | |
| Procept Biorobotics Corp | 0.8 | $3.0M | NEW | 79k | 38.15 | |
| Health Sciences Acq Corp 2 Ord Shs (HSAQ) | 0.7 | $3.0M | 300k | 9.89 | ||
| Environmental Impact Acqu Com Cl A (ENVI) | 0.7 | $3.0M | NEW | 300k | 9.89 | |
| Medicus Sciences Acquisition Cl A Shs (MSAC) | 0.7 | $2.9M | 300k | 9.75 | ||
| Rocket Pharmaceuticals (RCKT) | 0.6 | $2.4M | -33% | 80k | 29.89 | |
| Celldex Therapeutics Com New (CLDX) | 0.5 | $2.2M | -19% | 40k | 53.99 | |
| Cyclacel Pharmaceuticals (CYCC) | 0.5 | $2.1M | +5% | 400k | 5.27 | |
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.5 | $2.1M | 2.0M | 1.04 | ||
| Intellia Therapeutics (NTLA) | 0.5 | $2.0M | +50% | 15k | 134.13 | |
| Harpoon Therapeutics (HARP) | 0.5 | $2.0M | +400% | 250k | 7.90 | |
| Global Blood Therapeutics In (GBT) | 0.5 | $1.9M | +275% | 75k | 25.48 | |
| United Therapeutics Corporation (UTHR) | 0.5 | $1.8M | NEW | 10k | 184.60 | |
| Acutus Medical (AFIB) | 0.4 | $1.8M | +150% | 200k | 8.84 | |
| Aldeyra Therapeutics (ALDX) | 0.4 | $1.7M | 198k | 8.78 | ||
| Seer Com Cl A Call Option (SEER) | 0.4 | $1.7M | NEW | 50k | 34.54 | |
| Horizon Therapeutics Pub L SHS (HZNP) | 0.4 | $1.6M | -40% | 15k | 109.53 | |
| Mereo Biopharma Group Ads (MREO) | 0.4 | $1.6M | 650k | 2.42 | ||
| Butterfly Network Com Cl A (BFLY) | 0.4 | $1.6M | +50% | 150k | 10.44 | |
| Lifesci Acquisition Ii Corp (LSAQ) | 0.4 | $1.5M | 150k | 9.80 | ||
| Schrodinger (SDGR) | 0.3 | $1.4M | 25k | 54.68 | ||
| Vaxcyte (PCVX) | 0.3 | $1.3M | 50k | 25.38 | ||
| Zymeworks (ZYME) | 0.3 | $1.1M | +29% | 39k | 29.04 | |
| Berkeley Lts (BLI) | 0.3 | $1.1M | NEW | 55k | 19.56 | |
| Amicus Therapeutics (FOLD) | 0.3 | $1.1M | NEW | 111k | 9.55 | |
| Galapagos Nv Spon Adr (GLPG) | 0.3 | $1.1M | 20k | 52.60 | ||
| Biohaven Pharmaceutical Holding (BHVN) | 0.3 | $1.0M | NEW | 7.5k | 138.93 | |
| Renovacor | 0.3 | $1.0M | NEW | 115k | 9.05 | |
| Chinook Therapeutics (KDNY) | 0.2 | $949k | -62% | 74k | 12.77 | |
| Pulmonx Corp (LUNG) | 0.2 | $900k | -58% | 25k | 36.00 | |
| Immatics *w Exp 07/01/2020 (IMTXW) | 0.2 | $800k | 190k | 4.21 | ||
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.2 | $779k | +25% | 100k | 7.79 | |
| Innate Pharma S A Sponsored Ads (IPHA) | 0.2 | $771k | NEW | 125k | 6.17 | |
| Xenon Pharmaceuticals (XENE) | 0.2 | $764k | NEW | 50k | 15.28 | |
| Tango Therapeutics | 0.2 | $647k | NEW | 50k | 12.94 | |
| Cytomx Therapeutics (CTMX) | 0.2 | $636k | +66% | 125k | 5.09 | |
| The Beauty Health Company *w Exp 05/04/2026 (SKINW) | 0.1 | $498k | -23% | 34k | 14.48 | |
| Keros Therapeutics (KROS) | 0.1 | $495k | NEW | 13k | 39.60 | |
| Aslan Pharmaceuticals Ads (ASLN) | 0.1 | $445k | NEW | 250k | 1.78 | |
| Immunovant Call Option (IMVT) | 0.1 | $261k | 30k | 8.70 | ||
| Corvus Pharmaceuticals (CRVS) | 0.1 | $242k | NEW | 50k | 4.84 | |
| Renovacor *w Exp 99/99/999 | 0.0 | $60k | NEW | 75k | 0.80 | |
| Medicus Sciences Acquisition *w Exp 02/12/2026 (MSACW) | 0.0 | $24k | 33k | 0.72 | ||
Past Filings by Affinity Asset Advisors
SEC 13F filings are viewable for Affinity Asset Advisors going back to 2020
- Affinity Asset Advisors 2021 Q3 filed Nov. 12, 2021
- Affinity Asset Advisors 2021 Q2 filed Aug. 13, 2021
- Affinity Asset Advisors 2021 Q1 filed May 14, 2021
- Affinity Asset Advisors 2020 Q4 filed Feb. 12, 2021